Publisher
Springer Nature Singapore
Reference67 articles.
1. Aguzzi A, Wagner EF, Williams RL, Courtneidge SA (1990) Sympathetic hyperplasia and neuroblastomas in transgenic mice expressing polyoma middle T antigen. New Biol 2:533–543
2. Almstedt E, Elgendy R, Hekmati N, Rosen E, Warn C, Olsen TK, Dyberg C, Doroszko M, Larsson I, Sundstrom A, Arsenian Henriksson M, Pahlman S, Bexell D, Vanlandewijck M, Kogner P, Jornsten R, Krona C, Nelander S (2020) Integrative discovery of treatments for high-risk neuroblastoma. Nat Commun 11:71
3. Althoff K, Beckers A, Bell E, Nortmeyer M, Thor T, Sprussel A, Lindner S, De Preter K, Florin A, Heukamp LC, Klein-Hitpass L, Astrahantseff K, Kumps C, Speleman F, Eggert A, Westermann F, Schramm A, Schulte JH (2015) A Cre-conditional MYCN-driven neuroblastoma mouse model as an improved tool for preclinical studies. Oncogene 34:3357–3368
4. Alvarez-Leon W, Mendieta I, Delgado-Gonzalez E, Anguiano B, Aceves C (2021) Molecular iodine/cyclophosphamide synergism on Chemoresistant neuroblastoma models. Int J Mol Sci 22:8936
5. Anderson NM, Qin X, Finan JM, Lam A, Athoe J, Missiaen R, Skuli N, Kennedy A, Saini AS, Tao T, Zhu S, Nissim I, Look AT, Qing G, Simon MC, Feng H (2021) Metabolic enzyme DLST promotes tumor aggression and reveals a vulnerability to OXPHOS inhibition in high-risk neuroblastoma. Cancer Res 81:4417–4430